A Rare Case of Congenital Choledochal Cyst (CCC) Resulting in Recurrent Acute Pancreatitis in an Otherwise Healthy Young Woman

Introduction: Congenital choledochal cyst (CCC) is a rare cystic dilatation of intrahepatic or extrahepatic biliary ducts. We present a case of a type IVb choledochal cyst presenting as recurrent acute pancreatitis in a young healthy female with initial negative screenings. Case Description/Methods: An 18-year-old-female with a history of COVID-19 presented to the emergency department with one month of persistent abdominal pain, nausea, and vomiting. She was hospitalized once prior for similar symptoms and was diagnosed with acute pancreatitis. This admission, blood work showed elevated lipase, elevated liver enzymes, mild bilirubinemia with a normal lipid panel and urine was significant for infection. She received fluids, antiemetics and was started on prophylactic antibiotics for ascending cholangitis. A right upper quadrant ultrasound ruled out cholelithiasis or acute cholecystitis, but showed dilation of the common bile duct. MRCP confirmed dilation with bulbous termination in the periampullary region diagnosed as type IVb choledochal cyst. Discussion(s): CCCs are rare in Western countries with an incidence between 1 in 100,000 to 150,000. 80% of these cysts are diagnosed in patients under the age of 10. They are difficult to diagnose due to variable clinical presentations. A study of 214 CCC patients demonstrated the most common symptom was abdominal pain, followed by jaundice and fever. When cysts are found in adults, symptoms resemble atypical acute biliary tract disease. Surgical cyst removal may be needed for patients with significant risk factors such as older age and age of symptom onset, due to increased risk of malignant transformation. Longer periods of observation have been documented to be associated with an increased chance of developing late complications, such as anastomotic stricture, biliary calculi and recurrent cholangitis. Type IVb CCCs, as seen in this case, consist of multiple extrahepatic cysts and hepaticojejunostomy is the treatment. This patient's young age and recurrent acute pancreatitis combined with her lab and imaging findings strongly suggest the diagnosis of CCC. The anatomical location of the CCC impeded flow of pancreatic enzymes through the ampulla of vater, leading to recurrent pancreatitis in an otherwise healthy young female. CCC, although very rare, should be considered in the differential of acute pancreatitis when other causes such as gallstones and heavy alcohol consumption cannot be identified, as prompt diagnosis and surgical removal is imperative.

POSA310 Artificial Intelligence Applied on Administrative Big Data to Predict the Severity of SARS-COV-2 Infection

Objectives: To estimate the prognostic factors underlying severity of Sars-Cov-2 infection using a machine learning approach. Methods: The analysis is based on administrative databases of Italian Entities. Patients who were hospitalized with COVID-19 diagnosis (ICD-9 078.89) after 1st January 2020 were included into the dataset together with 13 relevant features representing age, sex and clinical history of each patient. Each record was labelled as 0 (hospitalized patients) or 1 (patients in intensive care or deceased). KerasTuner was used to define the architecture of the Neural Network achieving good accuracy score. To identify prognostic factors underlying severity of Sars Cov-2 infection, feature’s importance was evaluated starting from a Random Forest Classifier. Results: The preliminary dataset built contains 10.448 records from 9.346 hospitalized patients. The selected neural network is made of 13 input nodes, each one representing a feature, 1024 nodes in the hidden layer, processing information that comes from the input layer, and 2 nodes in the output layer, each one representing a label to define patient’s condition. The neural network obtained was able to achieve 64% of accuracy on the testing set. The condition of approximately 2 out of 3 patients was correctly predicted just by analysing their features. The feature’s importance computed from the Random Forest Classifier indicated that patient’s age is the primary prognostic factor underlying severity of Sars Cov-2 infection. The combination of the other features slightly improved model’s performance. Conclusions: The preliminary analysis shows that age is a prognostic factor of fundamental importance in defining the severity of Sars Cov-2 infection. The model obtained could be used to predict disease progression in patients most at risk by analysing their information in the databases. The model will be further improved through a process of feature selection to increase its accuracy and to allow the identification of other prognostic factors.

Anti-SARS-CoV-2 antibody levels and kinetics of vaccine response: potential role for unresolved inflammation following recovery from SARS-CoV-2 infection.

The immune response after SARS-CoV-2 vaccine administration appears to be characterized by high inter-individual variation, even in SARS-CoV-2 positive subjects, who could have experienced different post-infection, unresolved conditions. We monitored anti-SARS-CoV-2 IgG levels and kinetics along with circulating biomarkers in a cohort of 175 healthcare workers during early immunization with COVID-19 mRNA-LNP BNT162b2 vaccine, to identify the associated factors. Subjects with a previous SARS-CoV-2 infection were characterized by higher BMI and CRP levels and lower neutrophil count with respect to naïve subjects. Baseline IgG levels resulted associated with CRP independently on BMI and inflammatory diseases. Among 137 subjects undergoing vaccination and monitored after the first and the second dose, three kinetic patterns were identified. The pattern showing a rapid growth was characterized by higher IgG levels at baseline and higher CRP and MCHC levels than negative subjects. Subjects previously exposed to SARS-CoV-2 showed higher levels of CRP, suggesting persistence of unresolved inflammation. These levels are the main determinant of IgG levels at baseline and characterized subjects belonging to the best performing, post-vaccine antibody kinetic pattern.

Monoclonal antibody therapy for high-risk Coronavirus (CoViD-19) patients with mild to moderate disease presentation: An encouraging experience in Frosinone Hospital

Background and Aim: The coronavirus disease 2019 (CoViD-19) pandemic has caused a worldwide crisis and encouraged an urgent search for prevention and treatment of infection. SARS-CoV- 2 neutralizing monoclonal antibodies (NMA), that bind the viral spike glycoprotein, are a new treatment able to attenuate disease progression. In this observational study we reported our experience in the NMA treatment of early CoViD-19. Materials and Methods: From March to May 2021 we enrolled patients affected by CoViD-19 with risk factors to develop severe disease and early onset of symptoms (preferably within 72 hours, not more than 10 days). All patients were subjected to phone monitoring up to 30 days after drug administration. Results:We evaluated 40 patients (M/F 24/16;median age 58.5 years, IQR 12.25;median symptoms duration before treatment 5 days, IQR 2), of which 36 were treated with bamlanivimab/etesevimab association, 3 with casirivimab/imdevimab, 1 with bamlanivimab. Sixteen patients (40%) were affected by obesity, 21 (52.5%) by hypertension, 9 (22.5%) by diabetes, 8 (20%) by chronic lung disease, 7 (17.5%) by secondary immunodeficiency. Serious adverse events did not occur during infusion and follow up. Five patients (12.5%) developed severe CoViD-19 with lung failure and needed hospitalization. Of these, one patient died. Conclusions: SARS-CoV-2 NMA could be a valid therapeutic option to decrease hospitalization and mortality rate. However we need to select eligible patient, evaluating risk factors and early timing of intervention.